Novo Nordisk’s NVO stock declined 4.3% on Wednesday after Roche RHHBY announced a license and collaboration deal worth $5.3 ...

Viking Therapeutics eyes billion-dollar obesity drug markets with pivotal trials and major production deals. Read more about ...

Shares of Viking Therapeutics VKTX gained more than 11% on Wednesday after the company announced that it had signed a broad ...

Viking Therapeutics Inc.’s stock soared 8% Wednesday, after the maker of a promising weight-loss pill secured a manufacturing ...

Viking Therapeutics (VKTX), the developer of a promising experimental weight-loss drug, has announced a multi-year ...

Less than a year after CordenPharma earmarked a major chunk of change to beef up in peptide manufacturing for GLP-1s and ...

Viking Therapeutics (VKTX) announced that it has signed a broad, multi-year manufacturing agreement with CordenPharma, a contract development ...

With a diverse pipeline featuring oral drug candidates like VK2809 for NASH and NAFLD, VK5211 for hip fracture recovery, and VK2735 for weight loss, it’s advancing treatments across a range of ...

It plans to start a phase 3 study for the subcutaneous version of VK2735 in the second quarter. It's also running a phase 2 study for the oral version of its lead candidate. Elsewhere, Viking is ...

Conference call scheduled for 4:30 p.m. ET todayInitiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25Phase 2 VENTURE-Oral Dosing Trial Evaluating ...

VK2735 is such a profound contender that an Oppenheimer research analyst upgraded the price target to $138 per share on March 26, 2024. Viking is also working on an oral version of VK2735 which ...